Literature DB >> 32635634

Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record.

Fabio Pagni1, Umberto Malapelle2, Claudio Doglioni3, Gabriella Fontanini4, Filippo Fraggetta5, Paolo Graziano6, Antonio Marchetti7, Elena Guerini Rocco8,9, Pasquale Pisapia2, Elena V Vigliar2, Fiamma Buttitta7, Marta Jaconi1, Nicola Fusco8,9, Massimo Barberis8,9, Giancarlo Troncone2.   

Abstract

A meeting among expert pathologists was held in 2019 in Rome to verify the results of the previous harmonization efforts on the PD-L1 immunohistochemical testing by scoring a representative series of non-small cell lung cancer (NSCLC) digital slides. The current paper shows the results of this digital experimental meeting and the expertise achieved by the community of Italian pathologists. PD-L1 protein expression was determined using tumor proportion score (TPS), i.e., the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. The gold standard was defined as the final PD-L1 score formulated by a panel of seven lung committed pathologists. PD-L1 status was clustered in three categories, namely negative (TPS < 1), low (TPS 1-49%), and high (TPS ≥ 50%). In 23 cases (71.9%) PD-L1 staining was performed using the companion diagnostic 22C3 pharmDx kit on Dako Autostainer, while in nine (28.1%) cases it was performed using the SP263 Ventana kit on BenchMark platform. A complete PD-L1 scoring agreement between the panel of experts and the participants was reached in 57.1% of cases, whereas a minor disagreement in 16.1% of cases was recorded. Italian pathologists performed best in strong positive cases (i.e., tumor proportion score TPS > 50%), whereas only 10.8% of disagreement with the gold standard was observed, and 55.6% regarded a single challenging case. The worst performance was achieved in the negative cases, with 32.0% disagreement. A significant difference resulted from the analysis of the data separated by the different clones used: 22.3% and 38.1% disagreement (p = 0.01) was found in the group of cases analyzed by 22C3 and SP263 antibody clones, respectively. In conclusion, this workshop record proposed the application of a digital pathology platform to share controversial cases in educational meetings as an alternative possibility for improving the interpretation and reporting of specific histological tools. Due to the crucial role of PD-L1 TPS for the selection of patients for immunotherapy, the identification of unconventional approaches as virtual slides to focus experiences and give more detailed practical verifications of the standard quality reached may be a considerable option.

Entities:  

Keywords:  NSCLC; PD-L1; immunotherapy

Year:  2020        PMID: 32635634     DOI: 10.3390/cancers12071800

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  5 in total

1.  Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the "Programmed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinoma".

Authors:  Albino Eccher; Gabriella Fontanini; Nicola Fusco; Ilaria Girolami; Paolo Graziano; Elena Guerini Rocco; Maurizio Martini; Patrizia Morbini; Liron Pantanowitz; Anil Parwani; Anna Maria Pisano; Giancarlo Troncone; Elena Vigliar
Journal:  J Pathol Inform       Date:  2021-01-08

2.  PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols.

Authors:  Simona Crosta; Renzo Boldorini; Francesca Bono; Virginia Brambilla; Emanuele Dainese; Nicola Fusco; Andrea Gianatti; Vincenzo L'Imperio; Patrizia Morbini; Fabio Pagni
Journal:  Cancers (Basel)       Date:  2021-01-14       Impact factor: 6.639

Review 3.  Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems.

Authors:  Stefano Marletta; Nicola Fusco; Enrico Munari; Claudio Luchini; Alessia Cimadamore; Matteo Brunelli; Giulia Querzoli; Maurizio Martini; Elena Vigliar; Romano Colombari; Ilaria Girolami; Fabio Pagni; Albino Eccher
Journal:  J Pers Med       Date:  2022-06-29

4.  Digital Slide Assessment for Programmed Death-Ligand 1 Combined Positive Score in Head and Neck Squamous Carcinoma: Focus on Validation and Vision.

Authors:  Albino Eccher; Ilaria Girolami; Giancarlo Troncone; Liron Pantanowitz
Journal:  Front Artif Intell       Date:  2021-06-04

5.  Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe.

Authors:  Umberto Malapelle; Pasquale Pisapia; Antonino Iaccarino; Massimo Barberis; Claudio Bellevicine; Hans Brunnström; Dario de Biase; Giovanna De Maglio; Kajsa Ericson Lindquist; Matteo Fassan; Gabriella Fontanini; Elisa Gruppioni; Paul Hofman; Sabine Merkelbach-Bruse; Miguel A Molina Vila; Anaïs Pujals; Ida Rapa; Luisella Righi; Rafael Rosell; Oliver Schildgen; Verena Schildgen; Fernando C Schmitt; Giovanni Tallini; Sara Vander Borght; Elena Vigliar; Marco Volante; Svenja Wagener-Ryczek; Birgit Weynand; Giancarlo Troncone
Journal:  J Clin Pathol       Date:  2020-07-31       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.